SynthesisBMC immunology2025
Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis.
Synthesis in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Global trends and emerging hotspots in neuromyelitis optica spectrum disorder diagnostic research: A bibliometric analysis.Medicine · 2026Review
- The New Spine of Access to the Brain's Secrets: Extracellular Vesicles from Cerebrospinal Fluid Liquid Biopsies in CNS Diseases and Blood-Brain Barrier Research.Molecular neurobiology · 2026Review
- Interleukin-40 and Soluble CD40 Ligand in Multiple Sclerosis: Inflammatory Signals or Clinically Applicable Biomarkers?Medeniyet medical journal · 2026Article
- Intrathecal immunoglobulin production in the diagnosis, prognosis, and monitoring of autoimmune diseases of the central nervous system.Journal of translational autoimmunity · 2026Review
- Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the diagnostic value of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in multiple sclerosis (MS) and optic neuromyelitis optica spectrum disorders (NMOSD) and their relationship with disease prognosis by Meta-analysis, and to explore their potentials in early diagnosis of the disease and monitoring of its course.
methodsWe systematically searched China National Knowledge Infrastructure (CNKI), VIP database, Wanfang database, PubMed, Wiley online library, and web of science databases for relevant literature on GFAP in neuroimmune diseases, and the time limit for searching was from inception to December 1, 2024, and two evaluators independently assessed all the studies. Two evaluators independently assessed the quality of all the studies, evaluated the data in detail according to the criteria of risk of bias, and performed Meta-analysis using RevMan 5.4.1 software and STATA 18.
resultsThrough literature screening, 12 studies were finally included, involving a total of 1731 participants, of which 871 were in the control group and 869 were in the experimental group. Meta-analysis results showed that GFAP levels in MS patients were significantly higher than those in healthy control groups [MD = 0.98, 95% CI (0.70, 1.25), P < 0.0001]; NfL levels were also significantly higher than controls [MD = 0.76, 95% CI (0.06, 1.46), P = 0.03]. In patients with optic neuromyelitis optica spectrum disease (NMOSD), GFAP levels were significantly higher than controls [MD = 0.97, 95% CI (0.03, 1.91), P = 0.04]; NfL levels were also significantly higher than controls [MD = 0.24, 95% CI (0.02, 0.46), P = 0.03]. Analysis of different disease stages showed that compared with healthy controls, GFAP levels were significantly elevated in patients with MS in the deteriorating phase [MD = 2.38, 95% CI (1.40, 3.37), P < 0.0001], in the active phase [MD = 2.01, 95% CI 0.20, 3.82), P = 0.03], and in the remission phase at a lower level of elevated GFAP levels [MD = 1.33, 95% CI (0.20, 2.46), P = 0.02]. For GFAP survival analysis in MS patients, the results showed no statistical significance [HR = 1.78, 95% CI (0.47, 6.66), P = 0.39].
conclusionThe levels of GFAP and NfL in MS and NMOSD patients were significantly higher than those in healthy controls. GFAP levels demonstrate a progressive decline correlating with MS disease activity-from exacerbation through active to remission phases-yet remain persistently elevated compared to controls. These findings indicate its potential utility for MS diagnosis and disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.